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Altered Populations of 
Unconventional T Cell Lineages 
in Patients with Langerhans Cell 
Histiocytosis
Jenée Mitchell1,2, Egle Kvedaraite3,4, Tatiana von Bahr Greenwood3,4, Jan-Inge Henter3,4, 
Daniel G. Pellicci5,6, Stuart P. Berzins1,2,6 & George Kannourakis1,2
Langerhans cell histiocytosis (LCH) lesions are defined by the presence of CD1a+/CD207+ myeloid 
cells, but many other immune cells are present including unconventional T cells, which have powerful 
immunoregulatory functions. Unconventional T cell lineages include mucosal-associated invariant 
T (MAIT) cells, type I natural killer T (NKT) cells and gamma-delta (γδ) T cells, which are associated 
with many inflammatory conditions, although their importance has not been studied in LCH. We 
characterized their phenotype and function in blood and lesions from patients with LCH, and identified 
a deficiency in MAIT cell frequency and abnormalities in the subset distributions of γδ T cells and 
NKT cells. Such abnormalities are associated with immune dysregulation in other disease settings 
and are therefore potentially important in LCH. Our study is the first to recognize alterations to 
MAIT cell proportions in patients with LCH. This finding along with other abnormalities identified 
amongst unconventional T cells could potentially influence the onset and progression of LCH, thereby 
highlighting potential targets for new immune based therapies.
Langerhans cell histiocytosis (LCH) is a rare disease that most frequently affects children but can also occur in 
adults1. LCH is characterized by inflammatory lesions affecting one or more organs. Osseous and cutaneous tissue 
are the sites most frequently affected while liver, spleen and hematopoietic involvement are associated with an 
increased mortality risk2. All LCH lesions contain myeloid lineage cells that express CD1a and CD2072–4. These 
‘LCH cells’ form the characteristic LCH microenvironment alongside a cellular infiltrate of T cells, macrophages, 
eosinophils, neutrophils, B cells, plasma cells and multinucleated giant cells3,5. Immune cells are fundamental 
to the inflammation and subsequent organ damage seen in LCH, but the role of different lineages is not well 
understood and they have not been specifically targeted in therapies. Recent advances in our understanding of 
immune regulation coupled with the development of new immunotherapies suggests that immune cells within 
LCH lesions may be potential targets for new treatments.
Patients with LCH often have mutations in the mitogen-activated protein kinase (MAPK) cell signalling path-
way6–12 and show signs of immune dysregulation5,13–15, although the nature of these defects and their significance 
to the etiology of LCH is not fully understood. The composition and inflammatory characteristics of LCH lesions 
suggest a localised dysregulation of immune cells and a link between innate and adaptive immunity at the site of 
inflammation in LCH remains to be elucidated. The characteristic presence of LCH cells implies their involve-
ment in the pathogenesis of this disease and it is possible that they promote T cell signalling that leads to potent 
cytokine release within lesions. This hypothesis is consistent with the large number of activated T cells within 
LCH lesions5,13,16.
Interestingly, there are also signs of immune abnormalities outside of the lesions of patients with LCH. For 
example, there are reports of CD1a+ LCH-like cells with myeloid characteristics1,17,18 and increased Foxp3+ 
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regulatory T cells (Tregs)14 in the circulation of patients with active LCH that suggest altered immune regula-
tion in LCH. Other lineages of immune cells with known regulatory functions have not been well-studied in 
LCH patients. Prime candidates to investigate are unconventional T cells such as mucosal associated invariant T 
(MAIT) cells, gamma delta (γδ) T cells and type I natural killer T cells (referred to herein as NKT cells), which are 
all capable of rapid inflammatory cytokine responses that can trigger and potentiate innate and adaptive immune 
responses. These unconventional T cells are already proposed to play fundamental roles in regulating aspects 
of tumor immunity, infection and autoimmunity19–23, piquing our curiosity about their role in LCH. One study 
found γδ T cells at a high frequency in LCH lesions24 and there is overexpression of CD1D in LCH cells compared 
with skin-resident Langerhans cells (LCs)25. NKT cells respond to lipids presented by the major histocompatibil-
ity complex (MHC)-like molecule, CD1d, hence higher expression of CD1D in lesions suggests a potential role 
for NKT cells in LCH. MAIT cells were first associated with anti-microbial responses, but have more recently 
been found to have an altered function in colorectal tumors22,23 and type 2 diabetes26, and they are associated with 
several autoimmune diseases27,28. Like NKT cells, MAIT cells have not been studied in LCH, but expression of 
CD161 is a defining characteristic of MAIT cells, and it is noteworthy that the gene encoding for the C-type lectin 
receptor for CD161 (CLEC2D) is also overexpressed by LCH cells compared with skin-resident LCs25. A unique 
characteristic of unconventional T cells is their ability to produce large amounts of T helper (Th) 1 (TNF/IFNγ), 
Th2 (IL-4), Th10 (IL-10), or Th17 (IL-17) cytokines29–31 (also see review by Godfrey et al.32) depending on the 
setting. Consequently, unconventional T cells are a logical target of investigation in an inflammatory setting such 
as LCH. We therefore characterized the frequency and function of unconventional T cell lineages in blood and 
tissue lesions from patients with LCH and healthy individuals. We hypothesize that the immune dysregulation 
accompanying LCH progression is associated with abnormalities in unconventional T cells and that one or more 
of these lineages may represent a viable target for new treatments.
Results
Clinical details of patients with LCH. Our cohort included 11 male and 5 female patients with LCH aged 
from 22 months to 68 years (Table 1). The most commonly affected tissues were bone, skin and lung. With the 
exception of one patient, donors with active disease (AD) had no known prior treatment with steroids or chemo-
therapy at the time of specimen collection, but the majority of those with non-active disease (NAD) had received 
treatments (Table 1).
Patient 
Code
Specimen 
description Sex
Age at 
diagnosis
Tissues 
affected Treatment prior to specimen
Age at 
specimen
Disease status at 
specimen
Sequelae, other 
comments
1 Bone lesion M 68 Bone Previous irradiation at site of and excision of hip lesion 68 Active (AD)
Diabetes insipidus 
from age 55
1 Matched blood
2 Pulmonary lesion M 40 Lung Nil 40 AD Mild pulmonary fibrosis, smoker
2 Matched blood
3 Involved lymph node M 9 Bone, lymph node Nil 9 AD Skull defect
4 Blood M 18 months Skin Nil 13 Non-active (NAD)
5 Blood M 53 Bone, lung, bone marrow Vinblastine/prednisolone 64 NAD
Mild pulmonary 
fibrosis
6 Blood M 39 Lung Vinblastine/prednisolone 52 NAD
7 Blood F 60 Skin Methotrexate/prednisolone 64 NAD Leg scarring
8 Blood F 36 Bone Lesion excision 37 NAD
9 Blood F 25 Bone Vinblastine/prednisolone 42 NAD Ataxia at time of specimen
10 Blood M 41 Skin Nil 41 AD
11 Blood F 39 Bone, lung Nil 39 AD
12 Blood F 34 Lung Biopsy and vinblastine/prednisolone 54 NAD Long term pulmonary fibrosis
13 Bone lesion M 2 Bone Nil 2 AD
Mutation in 
BRAFV600, CNS-
risk lesion
13 Matched blood
14 Blood M 8 months Skin, lymph node, liver Nil 22 months AD
No detectable 
mutation in 
BRAFV600
15 Blood M 10 Bone, skin
Cytarabine, prednisolone and 
vinblastine (ceased 6 months prior to 
specimen)
12 AD
Diabetes insipidus, 
mutation in 
BRAFV600
16 Blood M 67 Bone, skin Nil 67 NAD
Table 1. Clinical details of study participants.
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Circulatory MAIT cell proportion is decreased in patients with LCH. Unconventional T cells were 
stringently identified according to the following criteria: MAIT cells were classified as CD3+Vα7.2 TCR+CD161+ 
lymphocytes, γδ T cells as CD3+γδ TCR+ and NKT cells as CD3+PBS44-loaded CD1d-tetramer+ lymphocytes. 
Specimens analyzed were from the blood of healthy donors and patients with LCH, and from lesions from 
patients with LCH (Fig. 1a). The frequency of MAIT cells expressed as a proportion of total T cells was signifi-
cantly lower in blood (p = 0.0010) and lesions (p = 0.0353) from patients with LCH compared to healthy donors 
(Fig. 1b). The measure of MAIT cell frequency can sometimes be confounded by downregulation of CD161, 
however the proportion of Vα7.2 TCR+CD161− T cells did not increase in blood and lesions from LCH donors 
(Fig. 1b). No substantial difference was seen in the proportions of γδ T cells or NKT cells across the groups 
(Fig. 1b). Interestingly, there was greater variability in the proportion of circulatory NKT cells in patients with 
LCH (range = 0.000% to 8.68%) compared to healthy donors (range = 0.005% to 0.871%) (Fig. 1b). Blood sam-
ples from patients with LCH were further stratified into AD and NAD, however there were no differences in the 
proportions of circulatory MAIT cells, γδ T cells or NKT cells (Fig. 1c). Thus, while no discernible differences 
were observed in unconventional T cells between samples from AD and NAD donors, MAIT cells were reduced 
in samples from LCH donors compared to healthy blood donors.
Comparing MAIT cell identification methods and proportions across age groups. We identified 
MAIT cells as CD3+Vα7.2 TCR+CD161+ lymphocytes, however a recently developed alternative is the use of 
5-OP-RU-loaded MR1 tetramer33. We conducted an analysis to confirm that both approaches identify the same 
cells. Indeed, we found that Vα7.2 TCR+CD161+ MAIT cells were almost exclusively 5-OP-RU-loaded MR1 
tetramer+ and 5-OP-RU-loaded MR1 tetramer+ MAIT cells were almost all Vα7.2 TCR+CD161+ (Fig. 2a), and 
importantly, that both approaches yielded similar data in analysis of LCH samples (Fig. 2b).
We also noted that MAIT cell frequency can fall with age in healthy individuals34,35, so it was important to 
establish if the abnormalities we observed in LCH patients may have been influenced by age. MAIT cell pro-
portions were plotted against age and a line of best fit was determined for healthy donors and for patients with 
LCH between the ages 37 to 68 (Fig. 2c). For healthy donors, a Spearman’s non-parametric correlation test (95% 
confidence interval) determined that MAIT cell proportion was not significantly (p = 0.31) correlated to age 
(r = −0.3), while in patients with LCH, MAIT cell proportion was significantly (p = 0.01) negatively correlated 
to age (r = −0.78) (Fig. 2c). Although there was no significant correlation for healthy donors, we do not exclude 
the possibility that an association may have been identified with an increased cohort and indeed, our data did 
suggest a slight trend. Importantly, however, there remained a significant (p = 0.0015) decrease in the propor-
tion of MAIT cells in total T cells when we compared the peripheral blood from patients with LCH age 37 to 68 
compared to healthy donors age 37 to 68 (Fig. 2d). Therefore age related changes in MAIT cell frequency do not 
account for the abnormalities we have observed in patients with LCH.
CD4+Vα7.2 TCR+CD161+ T cells are increased in patients with LCH. Given there are functionally 
distinct subsets of unconventional T cells, we next tested the relative frequency of several MAIT, NKT and γδ T 
cell subpopulations. MAIT cells were primarily identified as Vα7.2 TCR+CD161+ T cells and we examined CD8 
and CD4 subsets (Fig. 3a) and found that patients with LCH had an increased proportion of blood CD4+Vα7.2 
TCR+CD161+ T cells, and a similar trend was observed in lesions, although this was not significant (Fig. 3b). 
No differences were observed upon further stratification of LCH blood samples into AD and NAD (Fig. 3b). 
Although CD4+Vα7.2 TCR+CD161+ T cells are not exclusively 5-OP-RU-MR1 tetramer binding35, Eomes, PLZF 
and CCR4 expression is comparable in these populations irrespective of the gating method, thus CD4+Vα7.2 
TCR+CD161+ T cells are phenotypically similar to CD4+ 5-OP-RU antigen specific MAIT cells36.
Unusual γδ T cell and type I NKT cell phenotype in patients with LCH. Typically γδ T cells are 
CD8−CD4−, however there are known transcriptional differences between CD161+ and CD161− γδ T cells37. 
Therefore we compared the proportions of CD8−CD4−, CD8+(CD4−) and CD4+(CD8−) γδ T cells and 
CD8−CD161−, CD8+CD161− CD8−CD161+ CD8+CD161+ γδ T cell subsets in patients with LCH (Fig. 4a). We 
found a significant (p = 0.0465) increase in the proportion of CD4+(CD8−) γδ T cells from LCH lesions compared 
with healthy donors (Fig. 4b) but no discernible differences were detected in the CD161 subsets between the 
healthy donor and LCH patient groups (Fig. 4c).
For NKT cells we investigated CD8 and CD4 subsets and CD56 expression (Fig. 5a) and found that while there 
were similar proportions of circulatory CD56+ NKT cells (Fig. 5b) and CD8+ NKT cells (Fig. 5c) between patients 
with LCH and healthy donors there were trends toward a higher proportion of CD4+ and a lower proportion of 
CD8−CD4− NKT cells in blood from patients with AD compared to NAD (Fig. 5c). Interestingly we observed 
reduced circulatory CD8+CD161− NKT cells in patients with AD compared to healthy donors (Fig. 5d).
Activation status of unconventional T cells in patients with LCH. LCH lesions are thought to harbor 
activated T cells5,13,16 and we were therefore assessed CD25 expression in LCH donors. We unexpectedly did not 
identify any considerable CD25 expression by either MAIT cells or NKT cells in LCH lesions (Fig. 6a) and most 
CD25+ T cells within LCH lesions were CD4+Foxp3+ Tregs (Fig. 6b).
Expression of MR1 by LCH cells. While γδ T cells can be stimulated by antigen independently of MHC 
or MHC-like molecules, CD1d and MR1 are necessary for antigenic stimulation of NKT cells and MAIT cells 
respectively. It is already known that CD1D is expressed by LCH cells25, but MR1 has not been directly studied 
in the context of LCH. MR1 is ubiquitously expressed but it was possible that a defect could impact MAIT cells, 
so we tested for the expression of MR1 by purified LCH (CD1a+) cells using qPCR. We found that MR1 was 
expressed by LCH cells (delta Ct from reference gene RPLP0 values: −2.24 and −7.97). These results suggest 
that LCH cells can express MR1 and could potentially present MR1-restricted antigens to MAIT cells in lesions. 
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Figure 1. Circulatory and lesional unconventional T cell proportions in LCH. (a) Gating strategy for 
identifying MAIT cells (1st and 2nd columns), γδ T cells (3rd column) and type I NKT cells (4th column) from 
circulating lymphocytes in healthy donors (1st row) and patients with LCH (2nd row), and from lesional 
lymphocytes in patients with LCH (3rd row). (b) Proportions of MAIT cells and Vα7.2 TCR+CD161− T cells, 
γδ T cells and type I NKT cells in total T cells. (c) Proportions of MAIT cells, Vα7.2 TCR+CD161− T cells, γδ 
T cells and type I NKT cells in circulating T cells from patients with LCH (LCH-PB) stratified by active disease 
(AD) and non-active disease (NAD). Kruskal-Wallis tests with Dunn’s multiple comparisons were conducted 
for (b) and Mann Whitney tests for (c), error bars indicate median + interquartile range, 10−3 on logarithmic 
scale indicates ‘undetectable’.
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Figure 2. Comparing MAIT cell proportions across different identification methods and age groups. (a) Gating 
strategy for identifying 5-OP-RU-loaded MR1 tetramer+ cells within the Vα7.2 TCR+CD161+ T cell population 
(top row) and Vα7.2 TCR+ cells within the 5-OP-RU-loaded MR1 tetramer+CD161+ T cell population (bottom 
row) in peripheral blood from healthy donors (left) and patients with LCH (right). Data are representative of 
at least 3 individual donors per group. (b) Matched proportions of Vα7.2 TCR+CD161+ T cells and 5-OP-
RU-loaded MR1 tetramer+CD161+ T cells in total T cells from the peripheral blood of patients with LCH. 
(c) Proportions of MAIT cells in peripheral blood T cells from healthy donors (blue circles) and patients with 
active (AD) LCH (closed red circles) and non-active (NAD) LCH (open red circles) with imposed Gaussian 
distributions for each data set (dotted lines) and a line of best fit for healthy donors (solid blue line) and LCH 
patients (solid red line) aged 37–68, and for LCH patients aged 2–13 (red dashed line). (d) Proportions of MAIT 
cells in total T cells from the peripheral blood from healthy donors aged 37 to 68 and patients with LCH aged 
37 to 68. An unpaired t Test with Welch’s correction was conducted for (d), error bars indicate mean + 95% 
confidence interval.
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Importantly, MAIT cells can also be activated independently of antigen by IL-12 and IL-18, which is noteworthy 
because there are elevated levels of IL-18 in the peripheral blood from patients with LCH38.
Unconventional T cells from patients with LCH can produce Th1 cytokines. Next, we investigated 
the functional capacity of unconventional T cells from LCH patients as it was important to establish if these cells 
could mount a normal cytokine response to stimulation. We stimulated T cells with PMA and ionomycin and 
examined TNF and IFNγ production by MAIT cells (Fig. 7a), γδ T cells (Fig. 7b) and NKT cells (Fig. 7c). MAIT 
cells, NKT cells and γδ T cells from patients with LCH were able to produce TNF and IFNγ, albeit in small pro-
portions from one donor in particular (Fig. 7d). IL-4 and IL-17A cytokine production was negligible by all T cells 
in LCH and healthy donors (data not shown). Our data suggest that although decreased in proportion, the MAIT 
cells in patients with LCH are functionally competent. It is important to note, however that more subtle defects 
may become evident with different forms of activation.
Relative frequency of circulatory MAIT cells during AD and NAD and the effects of treatment. 
Given our observation that MAIT cells are reduced in the circulation of patients with LCH, and their known 
immunoregulatory ability, we conducted a longitudinal analysis of MAIT cells at different stages of disease and 
treatment following lesion excision and during chemotherapy in two patients at a number of time points for a 
period of 20 to 25 months (Fig. 8). We observed minor changes in the MAIT cell proportion and total lymphocyte 
count of one patient with AD who was receiving vinblastine or methotrexate and prednisolone. More interest-
ingly, the MAIT cell frequency of the other patient increased during treatment with vinblastine and prednisolone 
and decreased at cessation of treatment when the patient had NAD. Furthermore, this patient’s MAIT cell pro-
portion increased when the disease reactivated and treatment recommenced. Whether the changes in MAIT cell 
proportion were disease specific or treatment specific was not established, but this is an indication that MAIT cell 
frequency could potentially be associated with LCH disease activity.
Discussion
Unconventional T cells include several immunoregulatory lineages but have been difficult to study due to low 
numbers and a lack of reagents to enable stringent identification and functional analysis. Improved knowledge 
about these cells and our access to important reagents enabled us to characterize MAIT cells, NKT cells and γδ T 
cells and determine if there were defects in their frequency or cytokine production.
MAIT cells were reduced in proportion in the blood from patients with LCH and the lesional proportions 
were consistent with that seen in the blood from patients. Interestingly, the proportion of circulating MAIT cells 
was similar in patients with AD and NAD, which suggests that a MAIT cell deficiency may precede the onset of 
AD and could be a potential predisposing factor for LCH. Of note, longitudinal analysis of one patient revealed a 
substantial rise in MAIT cell frequency after treatment and a subsequent fall when treatment ceased and the dis-
ease was non-active. Fluctuations in MAIT cell proportion, which were remarkably at approximately 17% of total 
Figure 3. MAIT cell subsets in LCH. (a) Gating strategy for identifying CD8 and CD4 cells in MAIT cells from 
the peripheral blood from healthy donors (top left) and LCH patients (PB) (top right), and in lesional MAIT 
cells from patients with LCH (bottom left). (b) Proportions of CD4+, CD8+, and CD8−CD4− cells in MAIT cells 
from the peripheral blood from healthy donors (HD), patients with non-active LCH (PB-NAD) and active LCH 
(PB-AD) and in lesional MAIT cells from patients with active LCH. Kruskal-Wallis tests with Dunn’s multiple 
comparisons were conducted for (b) except where only two groups were compared (Mann Whitney test), error 
bars indicate median + interquartile range, 10−3 on logarithmic scale indicates ‘undetectable’.
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T cells for three separate time points, will be interesting to pursue in a cohort of LCH donors. Albeit in a single 
donor, the changes are consistent with our hypothesis that increasing MAIT cell frequency could be beneficial in 
the resolution of LCH. It is vital to emphasise that the result is a very preliminary observation. We did not observe 
an increase in γδ T cells reported by Alaibac and Chu24, although an important difference in our study was that we 
assayed lesions from various tissue sites, whereas the earlier study was limited to cutaneous lesions.
Unconventional T cells include several functionally distinct lineages and it was noteworthy that there were 
changes in subset proportions of γδ T cells and NKT cells as well as in the relative frequency of MAIT cells. γδ T 
cells do not usually express CD4, but we unexpectedly identified an increase in the proportion of lesional CD4+ 
γδ T cells. Determining the cause and functional significance of this is outside the scope of this study, but it was 
interesting that we also detected an increase in the proportion of CD4+Vα7.2 TCR+CD161+ T cells in patients 
with LCH. As with γδ T cells, the CD4+Vα7.2 TCR+CD161+ T cells are usually a minor subset, but their increase 
in LCH parallels a similar observation reported for patients with colorectal cancer23. It is important to note, how-
ever, that this increase in CD4+Vα7.2 TCR+CD161+ T cells may be due to the overall reduction in MAIT cells.
The frequency of circulating NKT cells in healthy donors usually ranges from 0.01 to 0.1% of overall T cells, 
but is rarely greater than 1%39. Surprisingly, NKT cell frequency in patients with LCH was more variable and 
even extended to a patient where NKT cells comprised almost 9% of T cells in blood. A previous case study of 
Figure 4. γδ T cell subsets in LCH. (a) Gating strategy for identifying γδ T cell subsets. (b) Proportions of 
CD4+CD8−, CD8−CD4− and CD8+CD4− cells in γδ T cells from the peripheral blood from healthy donors 
(HD) and patients with LCH (PB) and in lesional γδ T cells from patients with active LCH. (c) Proportions of 
CD8−CD161+, CD8+CD161+, CD8+CD161− and CD8−CD161− cells in γδ T cells from the peripheral blood 
from healthy donors (HD) and patients with LCH (PB) and in lesional γδ T cells from patients with active 
LCH. Kruskal-Wallis tests with Dunn’s multiple comparisons were conducted for (b,c), error bars indicate 
median + interquartile range.
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an individual with 5% NKT cells was considered exceptional39 and it is noteworthy that the patient in our study 
had NAD at the time of sample collection, which followed a spontaneous disease resolution without treatment. 
Because NKT cells are immunoregulatory in nature, it would be interesting to determine if the high NKT cell 
Figure 5. NKT cell subsets in LCH. (a) Gating strategy for identifying type I NKT cell subsets in peripheral 
blood from healthy donors (HD) and patients with LCH (PB), and in lesions from patients with LCH. (b) 
Proportions of CD56+ cells in type I NKT cells. (c) Proportions of CD4+CD8−, CD8−CD4− and CD8+CD4− 
cells in type I NKT cells. (d) Proportions of CD8+CD161−, CD8+CD161+, CD8−CD161+ and CD8−CD161− 
cells in type I NKT cells. Kruskal-Wallis tests with Dunn’s multiple comparisons were conducted for (b–d) 
(LCH lesion group excluded due to sample size) except where only two groups were compared (Mann Whitney 
test), error bars indicate median + interquartile range, 10−3 on logarithmic scale indicates ‘undetectable’.
www.nature.com/scientificreports/
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frequency was pre-existing or accompanied this remission, which may indicate a direct role for NKT cells. In 
striking contrast were several patients with LCH that had undetectable NKT cells. This too is unusual in healthy 
individuals and such a deficit could be expected to have a large impact on immune regulation and potentially 
the progression of LCH. The factors controlling NKT cell frequency in humans are poorly understood but once 
determined, it will be interesting to assess if they are defective in LCH patient groups.
We investigated whether the frequency abnormalities of unconventional T cells extended to their functional 
capacity, as this has previously been reported for many patient groups, including with cancer23,40. Each T cell lin-
eage that we studied from patients with LCH retained the capability to produce Th1 cytokines after stimulation. 
High levels of IL-17A have been reported in the blood of patients with LCH41 and more controversially25,42 in 
lesions43. Our findings of negligible IL-17A production by T cells from patients with LCH indicates that T cells in 
LCH do not respond with rapid IL-17A release, although we cannot rule out that an in vivo stimulus could cause 
IL-17A production.
Having identified these immune abnormalities, it will be essential for future studies to determine their origin 
and whether they precede LCH, or are caused by it. An intriguing question is whether unconventional T cells are 
directly interacting with LCH cells and if so, whether this results in T cell activation, or affects the LCH cells. For 
example, in addition to cytokine release, activated MAIT cells express CD40L44, which can mature LCH cells in 
vitro and increase their allostimulatory capacity45. This implies that LCH cells could mature and present antigen 
more effectively in the presence of activated MAIT cells, which could promote inflammation and reduce Treg 
induction by immature myeloid cells, in turn resolving lesions.
We have shown for the first time that the frequency of unconventional T cells, especially MAIT cells, is abnor-
mal in patients with LCH. MAIT cell frequencies appear similar in the periphery of patients with AD and NAD, 
although an increase in proportion was observed upon treatment in one patient that suggested MAIT cells could 
be associated with LCH onset and progression, although further studies are required to confirm this. Changes in 
unconventional T cell subset distributions and frequency in patients with LCH are consistent with the established 
role of unconventional T cells in immune dysregulation. It will be especially informative to determine the direct 
Figure 6. Activation status of T cells in patients with LCH. (a) Representative plots demonstrate that most 
CD25+ T cells in LCH lesions are CD4+ (left) and there is little to no CD25 expression by MAIT cells (center) 
or type I NKT cells (right). (b) Representative plots demonstrate that most CD25+ T cells in lesions are 
CD4+Foxp3+. Data are representative of at least 4 individual donors in (a) and 3 individual donors in (b).
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roles of these cells in LCH and whether the abnormalities we have identified are a cause or consequence of the 
disease. Our analysis strengthens earlier reports of immune dysfunction in LCH by showing the abnormalities 
extend beyond Foxp3+ Tregs to unconventional T cell lineages that could be equally important factors in LCH. 
Their distinctive functions and the development of specific agonists make unconventional cells promising candi-
dates as biomarkers or targets of immune based therapies, but more detailed analysis is now required for transla-
tion to clinical applications.
Materials and Methods
Human blood and tissue. This research was approved by the Ballarat Health Services and Saint John of 
God Ballarat Hospital Human Research Ethics Committee (HREC) (HREC/15/BHSSJOG/5 and HREC/10/
BHSSJOG/57) and Federation University Australia HREC (A08-100) and the methods were carried out in 
accordance with the approved guidelines. Patients, and/or parents of children with LCH where appropriate, pro-
vided written informed consent. Healthy donor peripheral blood mononuclear cells (PBMCs) were obtained 
from the Australian Red Cross Blood Service.
Figure 7. Th1 cytokine production by unconventional T cells. Gating strategy for post stimulation 
identification of TNF and IFNγ producing MAIT cells (a), γδ T cells (b) and type I NKT cells (c) from the 
peripheral blood from healthy donors (HD) and patients with LCH (PB), and from lesional T cells from patients 
with active LCH. (d) Proportions of TNF+ and/or IFNγ+ T cells in MAIT cells, γδ T cells and type I NKT cells 
from the peripheral blood from healthy donors (HD), patients with non-active LCH (PB-NAD) and active 
LCH (PB-AD) and in lesional T cells from patients with active LCH. Kruskal-Wallis tests with Dunn’s multiple 
comparisons were conducted for (d) (groups with only one value excluded), except where only two groups were 
compared (Mann Whitney test), error bars indicate median + interquartile range, 10−3 on logarithmic scale 
indicates ‘undetectable’.
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Healthy donor PBMCs were isolated with Histopaque-1077 (Sigma-Aldrich). PBMCS were isolated from the 
peripheral blood from patients with LCH using Histopaque-1077 or Lymphoprep (Axis-Shield PoC AS, Oslo, 
Norway), otherwise white blood cells were isolated using an in house red cell lysis buffer. Tissue was processed 
using MACS tumour dissociation kit for humans (Miltenyi Biotec) as per manufacturer’s instructions. Different 
methods were used to achieve a single cell suspension for lesions and for some LCH peripheral blood samples 
compared to healthy donors, therefore flow cytometry analysis was conducted relative to the CD3+ (T cell) pop-
ulation or sub-populations thereof. LCH lesions and matched peripheral blood samples are colour coded for 
tracking throughout the figures.
Surface antibody staining. Cells were stained with viability dye 7-aminoactinomycin D (7-AAD; 
BD Pharmingen) and anti-human cell surface antibodies from the following list: CD1a-BV605 (SK9; BD 
Biosciences),CD3-Pacific Blue (HIT3a; BioLegend), CD3-BV605 (HIT3a; BD Horizon), CD3-BV650 (UCHT1; 
BD Horizon), CD4-PE-Cy7 (SK3; BD Pharmingen), CD4-BV650 or -BV711 (SK3; BD Horizon), CD8-BV510 
(RPA-T8; BD Horizon), CD25-PE-Cy7 (M-A251; BD Pharmingen), CD56-BV786 (NCAM16.2; BD Horizon), 
CD127-BV421 (HIL-7R-M21; BD Horizon), CD161-APC or -PE/Dazzle 594 (HP-3G10; BioLegend), TCR 
Vα7.2-FITC (3C10; BioLegend), and TCRγ/δ-1-PE-Cy7 (11F2; BD Biosciences).
For identification of NKT cells, cells were stained with PBS44 loaded human CD1d tetramers. PBS44-CD1d 
monomers were kindly donated by Dale Godfrey (Dept. Microbiology and Immunology, Peter Doherty 
Institute, University of Melbourne, Parkville, Australia). In some instances, MAIT cells were identified using 
5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) loaded human MR1 tetramers. 5-OP-RU-MR1 
monomers were a kind gift from the McCluskey laboratory (Dept. Microbiology and Immunology, Peter Doherty 
Institute, University of Melbourne, Parkville, Australia). CD1d and MR1 monomers were tetramerized by conju-
gation to PE streptavidin (BD Pharmingen).
Foxp3 transcription factor staining. Following surface staining the eBioscience™ Foxp3/Transcription 
Factor Staining Buffer Set (ThermoFisher Scientific) was used as per manufacturer’s instructions.
Flow cytometry and fluorescence activated cell sorting. Analyses were performed using either a BD 
FACS Aria II cell sorter or BD LSR Fortessa. All cell sorting was performed using a BD FACS Aria II cell sorter 
and data analyzed using FlowJo software (Treestar). All analyses excluded dead cells and doublets.
RNA extraction, cDNA synthesis, transcriptome amplification and qPCR. Cells were purified by 
FACS (purity >90%), then the REPLI-g WTA Single Cell Kit (QIAGEN) for transcriptome amplification of small 
cell populations (<1000) was used to extract and reverse transcribe total RNA and amplify cDNA directly from 
Figure 8. Relative frequency of circulatory MAIT cells over time. Graphs show proportions of MAIT cells in 
total T cells and the corresponding total lymphocyte counts over a period of months following lesion excision 
and during chemotherapy. Patient 1 received vinblastine or methotrexate and prednisolone for the duration of 
the period. Patient 2 received vinblastine and prednisolone.
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cells, as per manufacturer’s instructions using a thermal cycler (Applied Biosystems Gene Amp® PCR System 
2700). RT2 SYBR® Green qPCR Mastermix (QIAGEN), Nuclease-Free Water (QIAGEN) and RT2 qPCR Primer 
Assays for MR1 (QIAGEN) and reference gene RPLP0 (QIAGEN) were combined with cDNA as per manufactur-
er’s instructions. No-template control samples were included for each component, substituting cDNA volumes 
with nuclease free water. Aliquots of each component were added to 0.1 mL strip tubes (QIAGEN) in triplicate 
and capped then placed in the Rotor-Disk 72 Rotor (QIAGEN) and placed in the Rotor-Gene Q (QIAGEN) for 
qPCR cycling. Conditions for amplification, annealing, extension and melt curve analysis were as per QIAGEN 
RT2 qPCR primer assay instructions. Melt curve analysis was performed to confirm that specific product was 
amplified as indicated by the data sheet for each primer assay.
Unconventional T cell stimulation assay. CD3+ T cells were sorted with a purity above 95%, except 
from two LCH peripheral blood samples, which were above 92%, and rested overnight at 37 °C in TexMACS 
Medium (Miltenyi Biotec) with 10% Fetal Bovine Serum (Sigma-Aldrich) and 1x Penicillin-Streptomycin 
(Sigma-Aldrich), then stimulated for 5 hours with PMA (10 ng/mL) and ionomycin (1 μg/mL) in the immediate 
presence of GolgiPlug (BD Biosciences).
Fixation, permeabilization and intracellular cytokine staining. Following stimulation assays and 
surface staining, cells were fixed and permeabilized using BD Cytofix/Cytoperm kit (BD Biosciences) as per man-
ufacturer’s instructions. Cells were then stained for intracellular cytokines from the following list: IL-4-APC (BD 
Pharmingen), TNFα-APC-Cy7 (MAb11; BioLegend), IFNγ-BV711 (B27; BD Horizon) IL-17A-BV786 (N49-653; 
BD Horizon).
Statistics. Data were analyzed using GraphPad Prism (GraphPad Software). Three donor matched blood and 
LCH lesions were available for the initial characterization of MAIT cells and NKT cells and one for the character-
ization of γδ T cells and the PMA and ionomycin stimulation of unconventional T cells. D’Agostino and Pearson 
omnibus normality tests (alpha = 0.05), were used to select parametric or non-parametric analysis. Differences 
were considered statistically significant at an alpha level of 0.05.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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